G1 Therapeutics, Inc. (GTHX) financial statements (2021 and earlier)

Company profile

Business Address 700 PARK OFFICES DRIVE
RESEARCH TRIANGLE PARK, NC 27709
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments207269369104
Cash and cash equivalents207269369104
Restricted cash and investments00  
Receivables0   
Other undisclosed current assets9211
Total current assets:216271370105
Noncurrent Assets
Operating lease, right-of-use asset810
Property, plant and equipment2411
Regulated entity, other noncurrent assets1   
Other undisclosed noncurrent assets10  
Total noncurrent assets:121411
TOTAL ASSETS:229285371105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20191212
Accounts payable4434
Accrued liabilities161598
Deferred revenue0 
Other liabilities31  
Total current liabilities:23201212
Noncurrent Liabilities
Long-term debt and lease obligation810  
Operating lease, liability810
Liabilities, other than long-term debt  00
Other liabilities  00
Other undisclosed noncurrent liabilities12   
Total noncurrent liabilities:281000
Total liabilities:51291212
Stockholders' equity
Stockholders' equity attributable to parent17725635993
Common stock0000
Treasury stock, value(0)(0)(0)(0)
Additional paid in capital613592573223
Accumulated deficit(436)(337)(214)(129)
Total stockholders' equity:17725635993
TOTAL LIABILITIES AND EQUITY:229285371105

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:45   
Operating expenses(142)(129)(89)(61)
Operating loss:(96)(129)(89)(61)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(1)741
Interest and debt expense(1)   
Other undisclosed income from continuing operations before equity method investments, income taxes1   
Loss from continuing operations before income taxes:(98)(122)(85)(60)
Income tax expense(1)   
Net loss attributable to parent:(99)(122)(85)(60)
Preferred stock dividends and other adjustments   (5)
Net loss available to common stockholders, diluted:(99)(122)(85)(65)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(99)(122)(85)(60)
Comprehensive loss, net of tax, attributable to parent:(99)(122)(85)(60)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: